U.S. Gas Utilities Stock News

NYSE:SPOT
NYSE:SPOTEntertainment

Will Spotify’s New Kid Controls and AI Labels Subtly Recast Its Platform Quality Narrative (SPOT)?

Spotify recently expanded parent-managed accounts for kids to its free tier across major markets and introduced tools that label AI-assisted music and remove low-quality generative content, aiming to strengthen safety and transparency on its platform. These changes highlight how content controls and AI disclosure are becoming central to Spotify’s product differentiation as regulators increase scrutiny of digital platforms. We’ll now examine how Spotify’s new parental controls and AI...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Protagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate Open

Protagonist Therapeutics (PTGX) moved 5.7% higher as investors bought into a broad biotech rally, with the stock participating in a sector wide rotation into biotechnology rather than reacting to company specific headlines. See our latest analysis for Protagonist Therapeutics. With Protagonist Therapeutics trading at US$140.91 and logging a 24.85% 1 month share price return and 61.63% year to date share price return, the strong 1 year total shareholder return of 153.98% and very large 3 year...
NYSE:MTDR
NYSE:MTDROil and Gas

Matador’s Weakest-In-Peer EBITDA Miss Might Change The Case For Investing In Matador Resources (MTDR)

Earlier this year, Matador Resources reported quarterly results that fell short of analysts’ revenue and EBITDA estimates, marking the weakest performance among its U.S. shale exploration and production peers. This earnings disappointment raises questions about how effectively Matador’s operations and midstream expansion are translating into financial resilience relative to competitors. Next, we’ll examine how this earnings miss, particularly on EBITDA, could affect Matador’s previously...
NasdaqGS:ETOR
NasdaqGS:ETORCapital Markets

eToro Group (ETOR) Slides As Bullish Fair Value Narrative Faces A Fresh Test

Recent Trading Performance for eToro Group eToro Group (NasdaqGS:ETOR) has drawn investor attention after its stock closed at $35.98, with returns down 3.9% over the past day and down 8.1% over the past week. See our latest analysis for eToro Group. For eToro Group, the recent 1 day and 7 day share price declines come on top of a weaker 1 year total shareholder return. This suggests momentum has faded compared with the start of the year, even though the year to date share price return is...
NYSE:USB
NYSE:USBBanks

U.S. Bancorp (USB) Stock Could Be A Bargain As Fair Value Tops Earnings Price

U.S. Bancorp stock has delivered a 3 year return of 87.8%, yet the current checks suggest the shares may still trade below an intrinsic value estimate that screens as undervalued on both an Excess Returns model and earnings multiples. Over the past 3 years, U.S. Bancorp has returned 87.8%, which puts extra focus on whether recent gains have already captured most of the value in the business. New digital payment offerings such as Enhanced Payments can support expectations for more efficient...
NYSE:TWLO
NYSE:TWLOIT

Twilio (TWLO) Beats Q1 Expectations, Is The Stock Still Fully Valued?

Twilio Q1 beat puts recent share gains in focus Twilio (TWLO) drew fresh investor attention after reporting Q1 revenue growth of 20% year on year, a 4.7% beat versus analyst expectations, alongside stronger net revenue retention and billings estimates. See our latest analysis for Twilio. Twilio's strong Q1 has come on top of a sharp share price re-rating, with the stock up 42.0% over 90 days and a 1 year total shareholder return of 57.85%, although the 5 year total shareholder return is down...
NYSE:SPH
NYSE:SPHGas Utilities

Is Suburban Propane Partners (SPH) Undervalued After Industry Tailwinds Lifted Its Margin Outlook?

Recent industry commentary has put Suburban Propane Partners (SPH) in focus, citing the Oil and Gas Refining & Marketing MLP sector’s fee-based structure and tight refined-product inventories as supportive factors for margins and future earnings estimates. See our latest analysis for Suburban Propane Partners. At a share price of $18.12, Suburban Propane Partners has seen a 9.49% 1 month share price return, while its 1 year total shareholder return of 5.39% and 3 year total shareholder return...
NasdaqGS:TSLA
NasdaqGS:TSLAAuto

Tesla (TSLA) Must Recall Nearly 20,000 Vehicles After NHTSA Rejects Headlight Request

NHTSA denied Tesla's request to avoid recalling nearly 20,000 Model 3 and Model Y vehicles over headlight compliance issues. The decision requires Tesla, NasdaqGS:TSLA, to proceed with a recall to address potential safety risks. The affected vehicles are tied to concerns around headlight performance under U.S. safety regulations. Tesla, NasdaqGS:TSLA, is a major electric vehicle and clean energy company, so any safety related ruling tends to draw attention from both drivers and investors...
NYSE:AU
NYSE:AUMetals and Mining

AngloGold Ashanti Stock Leads 3 Balance Sheet Picks For Defensive Investors

With inflation trends easing in several major economies, central banks taking a data driven approach to rates, and earnings expectations increasingly tied to real cash generation, many investors are looking for companies that already show high return on equity, solid past performance and strong balance sheets. That is exactly what the Solid Balance Sheet and Fundamentals screener is built to highlight. In this article, you will see three stocks from the screener that combine quality...
NYSE:TRU
NYSE:TRUProfessional Services

Is TransUnion’s (TRU) Alternative Data Push Quietly Redefining Its Core Competitive Edge?

In July 2026, TransUnion enhanced its mortgage credit report by integrating TruVision Alternative Credit Attributes (ACA 2.0) from the FactorTrust Alternative Lending Database, giving lenders broader visibility beyond traditional credit data at no additional cost. This move deepens mortgage risk assessments by layering alternative financial signals alongside trended and soft-check data, aiming to sharpen early-stage underwriting decisions and improve overall decision quality for lenders...
NYSE:BMY
NYSE:BMYPharmaceuticals

Bristol Myers (BMY) Is Up 5.5% After FDA Accepts Mezigdomide NDA In Multiple Myeloma

In July 2026, Bristol Myers Squibb announced that the FDA accepted its New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone to treat relapsed or refractory multiple myeloma, backed by Phase 3 data showing a clinically meaningful improvement in progression-free survival versus standard of care. An interesting aspect of this update is that the SUCCESSOR-2 trial enrolled a heavily pretreated, mostly triple-class-exposed patient population, highlighting...
NasdaqCM:EOSE
NasdaqCM:EOSEElectrical

Is Eos Energy Enterprises (EOSE) Fully Priced As Defense And Revenue News Builds?

Eos Energy Enterprises (EOSE) is in focus after securing a Golden Dome for America contract to deploy its Z3 zinc-based long-duration storage for national defense, along with record preliminary quarterly revenue guidance and expanding utility-scale project activity. See our latest analysis for Eos Energy Enterprises. Despite the defense contract and growing utility-scale project activity, the stock’s recent momentum has been weak. The 30-day share price return is down 46.01% and the...
NYSE:GS
NYSE:GSCapital Markets

Is Goldman Sachs’ Earnings Beat, Higher Dividend And New Debt Issuance Altering The Investment Case For GS?

In mid-July 2026, Goldman Sachs reported second-quarter net income of US$6,628 million and sharply higher earnings per share versus a year earlier, while also lifting its quarterly dividend to US$5.00 per share and executing US$4,000 million of share repurchases under an ongoing buyback program. Alongside these results, Goldman Sachs completed and announced multiple fixed and variable-rate bond offerings totaling several billions of dollars, underlining its continued use of the debt markets...
NasdaqGM:AUPH
NasdaqGM:AUPHBiotechs

New LUPKYNIS Combo Study in Lupus Nephritis Might Change The Case For Investing In Aurinia (AUPH)

Aurinia Pharmaceuticals recently initiated PRESERVE, a Phase 4 multicenter US study evaluating LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab in approximately 150 lupus nephritis patients, with complete renal response at 6 months as the primary endpoint. This post-approval trial builds on LUPKYNIS’s status as the only FDA-approved oral therapy for lupus nephritis and the only treatment to show a statistically significant increase in complete renal response at 6 months,...
NYSE:JAN
NYSE:JANHealth Care REITs

3 Interest Rate Sensitive Stocks Investors Are Watching As Fed Rate Signals Turn Murky

Interest rate sensitive stocks are back in focus as investors try to read a quiet new Fed chair and cooling inflation data that hint at steady borrowing costs. When policy signals are fuzzy and volatility risks rise, companies with stronger balance sheets and lower risk profiles can stand out within sectors tied closely to interest rates. Using our Interest Rate Sensitive Sectors screener, this article will walk through 3 stocks that appear well positioned for the current debate over the...
NYSE:ECL
NYSE:ECLChemicals

Ecolab (ECL) In Focus As Oppenheimer Upgrade Tests An Undervalued Narrative

Oppenheimer upgrade puts Ecolab in focus Oppenheimer’s upgrade of Ecolab (ECL) to Outperform, citing improving momentum in its core businesses along with growing contributions from its Global High-Tech segment, has pushed the stock back onto investors’ radar. See our latest analysis for Ecolab. At a share price of $272.83, Ecolab’s stock has been relatively steady in the short term, with a modest 30 day share price return of 1.38%, while its 3 year total shareholder return of 48.80% points to...
NasdaqGS:BWIN
NasdaqGS:BWINInsurance

How Shifting Sentiment Around Growth and Risk Will Impact Baldwin Insurance Group (BWIN) Investors

In recent weeks, Baldwin Insurance Group has attracted renewed investor attention as market participants reassess the insurer’s growth profile, recent performance metrics, and overall risk-reward balance in light of shifting sentiment rather than specific corporate announcements. This sentiment-driven reappraisal is occurring despite a weaker longer-term shareholder outcome, highlighting how quickly expectations around Baldwin’s earnings outlook and risk exposure can change. With this...
NYSE:GXO
NYSE:GXOLogistics

GXO Logistics (GXO) Renews Castorama Partnership, Is The Recent Upside Already Priced In?

GXO Logistics (GXO) stock is back in focus after the company renewed its long running partnership with Castorama for Moissy-Cramayel operations in France, reinforcing its role in the retailer’s nationwide supply chain. See our latest analysis for GXO Logistics. Against this backdrop, GXO Logistics’ recent 7 day share price return of 6.8% and 1 month share price return of 11.12% stand in contrast to a 3 month share price decline of 8.79% and a 3 year total shareholder return that is down...
NYSE:HGV
NYSE:HGVHospitality

Hilton Grand Vacations (HGV) Following Its Loan Refinance Is The Stock Fully Valued

Hilton Grand Vacations (HGV) recently refinanced its existing Term Loan B, replacing the US$849 million facility due 2028 with an amended US$850 million term loan maturing in 2033, while keeping pricing at SOFR plus 200. See our latest analysis for Hilton Grand Vacations. Hilton Grand Vacations’ refinancing news comes after a mixed stretch for the stock, with the share price down 5.29% over 30 days but still achieving a 9.78% year to date share price return and a 24.79% five year total...
NYSE:BKSY
NYSE:BKSYProfessional Services

BlackSky Technology (BKSY) Could Be 45% Undervalued Following Gen 3 Defense Contract Wins

BlackSky Technology (BKSY) is back in focus after securing several U.S. government research and development contracts for its Gen-3 AI constellation, which is centered on real-time space-based intelligence and battle damage assessment capabilities. See our latest analysis for BlackSky Technology. Despite the contract wins, BlackSky Technology’s 30 day share price return is down 23.46% and the 90 day share price return is down 40.70%. However, the 3 year total shareholder return is up 44.47%,...